Complement Regulation to Undo Systemic Harm in Preeclampsia
clinical trial
Press Enter · cited answer in seconds
0 sources
Complement Regulation to Undo Systemic Harm in Preeclampsia
Summary
Complement Regulation to Undo Systemic Harm in Preeclampsia is a clinical trial[1].
Key Facts
- Complement Regulation to Undo Systemic Harm in Preeclampsia is in the country of United States[2].
- Complement Regulation to Undo Systemic Harm in Preeclampsia's instance of is recorded as clinical trial[3].
- Complement Regulation to Undo Systemic Harm in Preeclampsia's start time is recorded as +2021-09-13T00:00:00Z[4].
- Complement Regulation to Undo Systemic Harm in Preeclampsia's end time is recorded as +2023-09-13T00:00:00Z[5].
- Complement Regulation to Undo Systemic Harm in Preeclampsia's main subject is recorded as pre-eclampsia[6].
- Complement Regulation to Undo Systemic Harm in Preeclampsia's number of participants is recorded as {'unit': '1', 'amount': '+12'}[7].
- Complement Regulation to Undo Systemic Harm in Preeclampsia's title is recorded as Complement Regulation to Undo Systemic Harm in Preeclampsia: The CRUSH Study[8].
- Complement Regulation to Undo Systemic Harm in Preeclampsia's short name is recorded as CRUSH[9].
- Complement Regulation to Undo Systemic Harm in Preeclampsia's minimum age is recorded as {'unit': 'http://www.wikidata.org/entity/Q577', 'amount': '+13'}[10].
- Complement Regulation to Undo Systemic Harm in Preeclampsia's ClinicalTrials.gov ID is recorded as NCT04725812[11].
- Complement Regulation to Undo Systemic Harm in Preeclampsia's research intervention is recorded as eculizumab[12].
- Complement Regulation to Undo Systemic Harm in Preeclampsia's research intervention is recorded as complement inactivating agents[13].
- Complement Regulation to Undo Systemic Harm in Preeclampsia's research intervention is recorded as immunosuppressive drug[14].
- Complement Regulation to Undo Systemic Harm in Preeclampsia's research intervention is recorded as immunologic factor[15].
- Complement Regulation to Undo Systemic Harm in Preeclampsia's clinical trial phase is recorded as phase II clinical trial[16].
- Complement Regulation to Undo Systemic Harm in Preeclampsia's research site is recorded as Cedars-Sinai Medical Center[17].
- Complement Regulation to Undo Systemic Harm in Preeclampsia's research subject recruitment status is recorded as suspended[18].
- Complement Regulation to Undo Systemic Harm in Preeclampsia's study type is recorded as interventional study[19].